- Home
- BCC vs NAMS Comparison
BCC vs NAMS Comparison
Compare BCC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCC
- NAMS
- Stock Information
- Founded
- BCC 2004
- NAMS 2019
- Country
- BCC United States
- NAMS Netherlands
- Employees
- BCC N/A
- NAMS N/A
- Industry
- BCC RETAIL: Building Materials
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- BCC Consumer Discretionary
- NAMS Health Care
- Exchange
- BCC Nasdaq
- NAMS Nasdaq
- Market Cap
- BCC 3.2B
- NAMS 2.9B
- IPO Year
- BCC 2013
- NAMS N/A
- Fundamental
- Price
- BCC $86.36
- NAMS $25.09
- Analyst Decision
- BCC Buy
- NAMS Strong Buy
- Analyst Count
- BCC 7
- NAMS 9
- Target Price
- BCC $112.83
- NAMS $41.00
- AVG Volume (30 Days)
- BCC 373.0K
- NAMS 812.8K
- Earning Date
- BCC 08-04-2025
- NAMS 08-06-2025
- Dividend Yield
- BCC 6.80%
- NAMS N/A
- EPS Growth
- BCC N/A
- NAMS N/A
- EPS
- BCC 6.82
- NAMS N/A
- Revenue
- BCC $6,557,812,000.00
- NAMS $64,006,000.00
- Revenue This Year
- BCC N/A
- NAMS N/A
- Revenue Next Year
- BCC $4.46
- NAMS $73.09
- P/E Ratio
- BCC $12.67
- NAMS N/A
- Revenue Growth
- BCC N/A
- NAMS 762.15
- 52 Week Low
- BCC $80.01
- NAMS $14.06
- 52 Week High
- BCC $155.42
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- BCC 51.76
- NAMS 61.96
- Support Level
- BCC $80.01
- NAMS $24.73
- Resistance Level
- BCC $88.42
- NAMS $25.80
- Average True Range (ATR)
- BCC 2.67
- NAMS 1.29
- MACD
- BCC 0.44
- NAMS 0.17
- Stochastic Oscillator
- BCC 78.60
- NAMS 83.46
About BCC Boise Cascade L.L.C.
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.